MA34512B1 - Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine - Google Patents

Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine

Info

Publication number
MA34512B1
MA34512B1 MA35713A MA35713A MA34512B1 MA 34512 B1 MA34512 B1 MA 34512B1 MA 35713 A MA35713 A MA 35713A MA 35713 A MA35713 A MA 35713A MA 34512 B1 MA34512 B1 MA 34512B1
Authority
MA
Morocco
Prior art keywords
naphthalenyl
pyrazol
ethyl
methyl
solid forms
Prior art date
Application number
MA35713A
Other languages
English (en)
Inventor
Buchholz Jordi Benet
Fernandez Laura Puig
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA34512B1 publication Critical patent/MA34512B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES FORMES SOLIDES PRÉSENTANT UN FAIBLE DEGRÉ DE CRISTALLINITÉ OU PRATIQUEMENT AMORPHES DU SEL DE CHLORHYDRATE DE LA 4-[2-[[5-MÉTHYL-1-(2-NAPHTALÉNYL)-1H-PYRAZOL-3-YL]OXY]ÉTHYL]MORPHOLINE (P027) ET DES PROCÉDÉS POUR LEUR PRÉPARATION.
MA35713A 2010-08-09 2011-08-08 Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine MA34512B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382225A EP2426111A1 (fr) 2010-08-09 2010-08-09 Formes cristallines de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
PCT/EP2011/063583 WO2012019984A1 (fr) 2010-08-09 2011-08-08 Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine

Publications (1)

Publication Number Publication Date
MA34512B1 true MA34512B1 (fr) 2013-09-02

Family

ID=43244877

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35713A MA34512B1 (fr) 2010-08-09 2011-08-08 Formes solides amorphes du chlorhydrate de la 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine

Country Status (19)

Country Link
US (1) US9428462B2 (fr)
EP (2) EP2426111A1 (fr)
JP (1) JP5899214B2 (fr)
KR (1) KR20130095751A (fr)
CN (1) CN103052626B (fr)
AR (1) AR082608A1 (fr)
AU (1) AU2011288550A1 (fr)
BR (1) BR112013002651A2 (fr)
CA (1) CA2807855C (fr)
CO (1) CO6670586A2 (fr)
ES (1) ES2543429T3 (fr)
MA (1) MA34512B1 (fr)
MX (1) MX341711B (fr)
PH (1) PH12013500218A1 (fr)
PT (1) PT2603495E (fr)
RU (1) RU2013110313A (fr)
SG (1) SG187745A1 (fr)
TW (1) TW201219387A (fr)
WO (1) WO2012019984A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2415471A1 (fr) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2524694A1 (fr) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
EP2792352A1 (fr) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Combinaisons comprenants un ligand de receptor Sigma et un ligand de réceptor adrénergic-alpha-2
TW201607538A (zh) * 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
CA2933057A1 (fr) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Combinaisons de gabapentanoides et de ligands des recepteurs sigma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04364129A (ja) 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd ６−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
RU2417987C2 (ru) * 2004-08-27 2011-05-10 Лабораторьос Дель Др.Эстеве, С.А. Ингибиторы сигма-рецептора
EP1781618B1 (fr) * 2004-08-27 2012-10-03 Laboratorios Del Dr. Esteve, S.A. Inhibiteurs de recepteur sigma
EP1634872A1 (fr) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Dérivés de pyrazole en tant qu'inhibiteurs des récepteurs sigma
EP2191830A4 (fr) 2007-09-21 2011-11-23 Shionogi & Co Préparation solide comprenant un antagoniste du récepteur npyy5
EP2116539A1 (fr) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2113501A1 (fr) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. Pyrazoles de 5-Methyl-1-(naphthalen-2-YL)-1H- utiles en tant qu'inhibiteurs de récepteur sigma
EP2292236A1 (fr) * 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention ou le traitement de douleurs induites par la chimiothérapie
RU2559325C2 (ru) * 2009-11-25 2015-08-10 Лабораторьос Дель Др. Эстеве, С.А. Соли 4-[2-[[5-метил-1-(2-нафталинил)-1н-пиразол-3-ил]окси]этил]морфолина
EP2361904A1 (fr) 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. Chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine et formes cristallines correspondantes
EP2335688A1 (fr) * 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Compositions pharmaceutiques comprenant des ligands du récepteur sigma
EP2426112A1 (fr) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
EP2353598A1 (fr) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
HUE029738T2 (en) * 2010-02-04 2017-04-28 Esteve Labor Dr 4- [2 - [[5-Methyl-1- (2-naphthalenyl) -1H-pyrazol-3-yl] oxy] ethyl] morpholine hydrochloride polymorphs and solvates
EP2388005A1 (fr) * 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2415471A1 (fr) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2460519A1 (fr) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma pour la douleur du cancer des os

Also Published As

Publication number Publication date
MX341711B (es) 2016-08-31
KR20130095751A (ko) 2013-08-28
US20130150575A1 (en) 2013-06-13
AR082608A1 (es) 2012-12-19
WO2012019984A1 (fr) 2012-02-16
HK1186468A1 (en) 2014-03-14
BR112013002651A2 (pt) 2016-05-31
CA2807855A1 (fr) 2012-02-16
CA2807855C (fr) 2018-10-23
EP2603495A1 (fr) 2013-06-19
ES2543429T3 (es) 2015-08-19
PT2603495E (pt) 2015-08-28
SG187745A1 (en) 2013-03-28
CN103052626B (zh) 2017-06-06
RU2013110313A (ru) 2014-09-20
EP2603495B1 (fr) 2015-05-06
CO6670586A2 (es) 2013-05-15
MX2013001559A (es) 2013-03-07
AU2011288550A1 (en) 2013-02-21
JP2013533298A (ja) 2013-08-22
US9428462B2 (en) 2016-08-30
PH12013500218A1 (en) 2013-04-01
EP2426111A1 (fr) 2012-03-07
TW201219387A (en) 2012-05-16
JP5899214B2 (ja) 2016-04-06
CN103052626A (zh) 2013-04-17

Similar Documents

Publication Publication Date Title
MA34047B1 (fr) Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
EP4247369A4 (fr) Inhibiteurs 6,7-dihydro-pyrano[2,3-d]pyrimidine à substitution spirocyclique du mutant kras g12c
EP2307025A4 (fr) Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
EA201590330A1 (ru) Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения
TW201713640A (en) Bruton's tyrosine kinase inhibitors
EA201590748A1 (ru) Противовирусные соединения против rsv
WO2008011557A3 (fr) Inhibiteurs hétéroaryliques de la kinase rho
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MA38071B1 (fr) Formes cristallines d'un inhibiteur de facteur xia
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
PL2297120T3 (pl) Pochodne aminodihydrotiazyny jako inhibitory BACE do leczenia choroby Alzheimera
MA35643B1 (fr) Inhibiteur de cetp d'oxazolidinone bicyclique condensée
EA201071232A1 (ru) Триазины как ингибиторы киназы pi3 и mtor
WO2011046964A3 (fr) Inhibiteurs de tyrosine kinase de bruton
PH12014500122A1 (en) Inhibitors of bruton's tyrosine kinase
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
JO3398B1 (ar) مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
EA201100334A1 (ru) Бициклические производные триазола для лечения опухолей